-

02:23:52 PM

DCTH Stock News

DCTH - Delcath Systems Inc

09/27/23 4:05 PM

Nasdaq : DCTH

low float

Delcath Systems Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, in the form of a total of 86,000 shares of the Company's common stock, outside of the Company's Omnibus 2020 Equity Incentive Plan as amended,...

RHEA-AI

very positive

09/11/23 8:00 AM

Nasdaq : DCTH

low float

A Retrospective Comparative Study of Chemosat and SIRT Presented at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Annual Meeting

Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the details of an oral presentation by independent...

RHEA-AI

neutral

09/05/23 4:00 PM

Nasdaq : DCTH

conferenceslow float

Delcath Systems to Participate at the H.C. Wainwright 25th Annual Investor Conference on September 12 and 13, 2023

Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will participate at the H.C Wainwright 25 th Annual Global Investor Conference. Delcath CEO, Gerard Michel will present on September 13 at 11:00 AM ET. The Company's proprietary products, HEPZATO...

RHEA-AI

neutral

09/01/23 2:07 PM

Nasdaq : DCTH

fda approvallow float

Delcath Systems, Inc. Announces Additional $35 Million in Funding Tied to the FDA Approval of HEPZATO KIT™

Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today that it raised approximately $35 million through the exercise of all the Tranche A warrants issued as part the previously announced March 29, 2023 Private Investment in Public...

RHEA-AI

neutral

08/14/23 9:10 PM

Nasdaq : DCTH

fda approvallow float

Delcath Systems, Inc. Announces FDA Approval of HEPZATO KIT™ for the Treatment of Adult Patients with Unresectable Hepatic-Dominant Metastatic Uveal Melanoma

Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic cancers of the...

RHEA-AI

neutral

08/09/23 5:33 PM

Nasdaq : DCTH

earningslow float

Delcath Systems Reports Second Quarter 2023 Results and Provides Business Update

Has continued to communicate with the United States Food and Drug Administration as the agency continues its review of the HEPZATO KIT™ New Drug Application resubmission with an anticipated PDUFA date of August 14, 2023; Received stockholders approval for the potential issuance in excess of 19.99% of Delcath's outstanding common stock upon the...

RHEA-AI

neutral

08/03/23 8:30 AM

Nasdaq : DCTH

conferencesearningslow float

Delcath Systems to File Its Second Quarter 2023 10-Q the Week of August 7 and Expects to Host a Conference Call the Following Week

Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced that it plans to report the Company's 2 Q23 earnings and issue its Form 10- Q the week of August 7, 2023. Subsequently, shortly after the FDA's decision on its HEPZATO™ KIT's new drug...

RHEA-AI

neutral

06/21/23 4:10 PM

Nasdaq : DCTH

low float

Delcath Systems Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee and the Board of Directors, as a material inducement to employment for two...

RHEA-AI

very positive

06/20/23 8:30 AM

Nasdaq : DCTH

managementlow float

Delcath Systems Appoints Vojislav Vukovic as Chief Medical Officer

Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Dr. Vojislav "Vojo" Vukovic as its new Chief Medical Officer. Vukovic earned his MD from the University of Sarajevo, a MSc in Radiation Biology and a PhD in...

RHEA-AI

neutral

06/07/23 4:10 PM

Nasdaq : DCTH

low float

Delcath Systems Announces Sandra Pennell as Senior Vice President of Finance

Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce that the Company has appointed Sandra Pennell as its new Senior Vice President of Finance. Pennell joins the Company with over twenty-years of experience in a variety of...

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next

DCTH Data

IndustrySurgical and Medical Instrument Manufacturing
Websitehttp://delcath.com/
Security nameDelcath Systems Inc
SectorManufacturing
Tags
- Medical Specialties
- Health Technology
- Manufacturing
- Surgical and Medical Instrument Manufacturing
CountryUS

About Delcath Systems Inc

delcath systems, inc. (nasdaq- dcth) is a specialty pharmaceutical and medical device company focused on the treatment of primary and metastatic liver cancers. our proprietary product---melphalan hydrochloride for injection for use with the delcath hepatic delivery system (melphalan/hds)---is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure. delcath is in late-stage clinical development in the united states with initial commercial activities in europe, where the melphalan/hds is marketed as a ce marked device under the trade name delcath hepatic chemosat® delivery system for melphalan (chemosat). our commercial strategy for chemosat is to steadily grow clinical adoption in major european markets and utilize physician experience to support appeals for reimbursement. since launch over 250 chemosat treatments have been performed at over 20 leading european cancer centers. in 2016, we launched our focus pivotal study in hepatic dominant ocular